NCT04322890View on ClinicalTrials.gov

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

PHASE2RecruitingINTERVENTIONAL
Enrollment

6,000

Participants

Timeline

Start Date

April 16, 2020

Primary Completion Date

December 24, 2026

Study Completion Date

December 24, 2027

Conditions
Non Small Cell Lung CancerEGFR Gene MutationALK Gene MutationROS1 Gene MutationMET Gene Mutation
Interventions
DRUG

Osimertinib

Osimertinib 80mg, po, qd;

DRUG

Alectinib 150 MG

Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;

DRUG

Crizotinib 250 MG

Crizotinib 250 MG po bid.

DRUG

Savolitinib, Crizotinib.

Savolitinib, 300mg po qd.

DRUG

Chemotherapy

500mg, ivgtt, every 21day.

Trial Locations (1)

410013

RECRUITING

Yongchang Zhang, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT04322890 - Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | Biotech Hunter | Biotech Hunter